Quark Pharmaceuticals announced today the publication of data showing that one of its proprietary gene targets, RTP801, plays a role in cigarette smoke-induced pulmonary injury and emphysema.

In a paper published in Nature Medicine, researchers reported "increased levels of RTP801 mRNA and protein in the lungs of humans suffering from emphysema and in the lungs of mice exposed to cigarette smoke," Quark said. "Unlike normal mice, mice that could not express RTP801 did not develop emphysema following six months of intensive exposure to cigarette smoke."

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Sometimes genetic tests give inconclusive results and provide little reassurance to patients, the Associated Press reports.

Vox wonders whether gene-editing crops will be viewed similarly as genetically modified organisms of if people will give them a try.

In Science this week: research regulation and reporting requirement reform, and more.

NPR reports that government and private insurers are being slow to cover recently approved CAR-T cell therapies.

Aug
07
Sponsored by
Qiagen

This webinar will present the results of an evaluation of a web-based variant interpretation software system for clinical next-generation sequencing.